Showing results (861-870 of 1,008) with videos related to

Sort By:
Pageof 101
Cardiovascular Therapeutics|December 7, 2022
Knockdown of lncRNA XIST Ameliorates IL-1β-Induced Apoptosis of HUVECs and Change of Tissue Factor Level via miR-103a-3p/HMGB1 Axis in Deep Venous Thrombosis by Regulating the ROS/NF-κB Signaling PathwayGuangxin Cao, Hua Zhou, Dong Wang, et al.
Cardiovascular Therapeutics|December 7, 2022
HSPB1 Regulates Autophagy and Apoptosis in Vascular Smooth Muscle Cells in Arteriosclerosis ObliteransKeqin Chen, Changmiao Hou, Lei Xu, et al.
Cardiovascular Therapeutics|July 14, 2021
Correlation between Stroke Risk and Systolic Blood Pressure in Patients over 50 Years with Uncontrolled Hypertension: Results from the SYSTUP-India StudyRishi Sethi, J S Hiremath, V Ganesh, et al.
Cardiovascular Therapeutics|April 16, 2013
The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registryZanfina Ademi, Molla M Huq, Danny Liew, et al.
Cardiovascular Therapeutics|March 23, 2013
Admission heart rate predicts mortality following primary percutaneous coronary intervention for ST-elevation myocardial infarction: an observational studyAwsan Noman, Karthik Balasubramaniam, Rajiv Das, et al.
Cardiovascular Therapeutics|June 15, 2013
Predictive factors of vascular complications after transcatheter aortic valve implantation in patients treated with a default percutaneous strategyManolis Vavuranakis, Maria Kariori, Vassilis Voudris, et al.
Cardiovascular Therapeutics|June 19, 2013
Clinical application of adult stem cells for therapy for cardiac diseaseAli Ghodsizad, Arjang Ruhparwar, Viktor Bordel, et al.
Cardiovascular Therapeutics|July 20, 2013
GLP-1 receptor agonists: effects on cardiovascular risk reductionDaniel Lorber
Cardiovascular Therapeutics|July 11, 2013
eNOS overexpressing bone marrow cells are safe and effective in a porcine model of myocardial regeneration following acute myocardial infarctionMichael R Ward, Kim A Connelly, Ram Vijayaraghavan, et al.
Cardiovascular Therapeutics|December 5, 2012
Ranolazine maintained sinus rhythm in a patient with refractory symptomatic atrial fibrillationSamuel Sossalla, Christian Sohns, Joachim Seegers, et al.
Pageof 101